DSM-Firmenich's board has proposed Richard Ridinger, current director and chairman of speciality ingredient distributor Brenntag, to succeed Thomas Leysen as chairman, with shareholders set to vote on the appointment at an extraordinary general meeting on 19 October.

Leysen will step down as director and chair once his successor is elected, freeing him to devote more time to his other corporate and non-profit mandates.

Who is Richard Ridinger?

Ridinger is already a DSM-Firmenich director, which shortens the transition considerably. He is a German national and chairs Brenntag, the speciality ingredients distribution group — a vantage point on the ingredients supply chain that few incoming chairs of a major B2B beauty and nutrition supplier bring.

"Richard Ridinger brings extensive executive and board-level experience in global, innovation-led businesses across Pharma, Home & Personal Care and Nutrition & Health," the company said.

It added: "He has a deep understanding of the company, which positions him well to succeed Thomas and will provide continuity to execute the strategy and create long-term value for shareholders and other stakeholders."

For personal care buyers and formulators, continuity is the operative word. DSM-Firmenich's beauty arm — built on UV filters, peptides and actives — now gets a chair who knows the portfolio from inside the boardroom rather than arriving cold.

Why is Leysen leaving now?

The outgoing chair framed the timing around four completed or near-complete milestones: integration, portfolio pruning, leadership renewal and the margin programme.

"With DSM-Firmenich now fully operating as one company, the portfolio tuning nearing completion with the closing of the Animal Nutrition & Health sale foreseen later this year, the executive committee rejuvenated and the margin improvement programme well underway, it is an opportune moment to hand over to a new chair," Leysen said.

He added: "Richard has all the requisite experience to help bring DSM-Firmenich to the next level. It has been a pleasure and an honour to chair the board during the formative stages of this unique company."

The reference to the Animal Nutrition & Health divestment closing later this year signals that the post-merger reshaping of DSM-Firmenich is entering its final phase. Once ANH exits, the remaining group concentrates on Perfumery & Beauty, Taste, Texture & Health and Health, Nutrition & Care — the segments most relevant to cosmetics industry procurement.

What does the change mean for suppliers and customers?

Ridinger's own comments stressed the foundations rather than a new strategic direction.

"DSM-Firmenich has come a long way in recent years and today stands on a strong foundation for the future," he said. "I am deeply honoured by the board's trust, and I look forward to shaping the company's next chapter together with the board and the executive committee."

For customers of DSM-Firmenich's personal care ingredients, the practical readouts are:

• No announced strategy shift accompanies the succession; the company positions the handover as continuity.
• The margin improvement programme Leysen cited remains underway, which suppliers and buyers should continue to factor into pricing conversations.
• The ANH sale closing, expected later this year, completes the portfolio tuning and sharpens the group's focus on the remaining speciality segments, including beauty and personal care.

The 19 October extraordinary general meeting is the next concrete data point: shareholder approval would formalise Ridinger's appointment and trigger Leysen's departure from the board. Watch for the ANH transaction closing before year-end as the second milestone that closes out the formative chapter of the merged company.